SGEN Financial Facts
Revenue from collaboration and license agreements: 23.97MIncome (loss) from operations: -32.41M
See Full Income Statement
Total liabilities and stockholders' equity: 849.91M
Total long-term liabilities: 61.81M
See Full Balance Sheet
Seattle Genetics Inc. (SGEN) Earnings
|
Expand Research on SGEN
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -17.8% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +3.3% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/8/24 | Q423 | N/A | -$0.95 | N/A | N/A | $682.86M |  |
N/A | N/A | ||
| 11/1/23 | Q323 | -$1.15 | -$0.82 | -$0.33 | $571M | $635.08M | |
 | | Details | |
| 8/2/23 | Q223 | -$1.13 | -$0.80 | -$0.33 | $603.83M | $560.64M | |
| | Details | |
| 4/27/23 | Q123 | -$0.93 | -$0.83 | -$0.10 | $519.72M | $514.99M | |
| | Details | |
| 2/15/23 | Q422 | -$0.80 | -$1.03 | +$0.23 | $528.15M | $479.84M | |
| | Details | |
| 10/27/22 | Q322 | -$1.03 | -$0.95 | -$0.08 | $510M | $459.58M | |
| | Details | |
| 7/28/22 | Q222 | -$0.47 | -$0.85 | +$0.38 | $498M | $438.23M | |
| | Details | |
| 4/28/22 |  |
Q122 | -$0.74 | -$1.00 | +$0.26 | $426.5M | $402.86M | |
| | Details |
